diphtheria, tetanus and whole cell pertussis vaccine

Trade name: Boostrix

Vaccineapproved

Approved

May 3, 2005

The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest. — Wikipedia

Clinical trial activity

37 trials · 31 clinical orgs · 2 marketing orgs

Phase 1
5
Phase 2
17
Phase 3
12
Phase 4
17

Earliest trial started Jan 1, 2002 (NCT01277705)

Timeline

1940s

  1. Jul 1, 1948

    Evidence of US Marketing

2000s

  1. Jan 1, 2002

    GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)

  2. May 3, 2005

    GlaxoSmithKline — Earliest FDA Approval

  3. May 3, 2005

    GlaxoSmithKline — NDA Secondary Org

  4. May 3, 2005

    GlaxoSmithKline — NDA Organization

  5. Jun 10, 2005

    Sanofi-Aventis — NDA Secondary Org

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedMay 3, 2005
  • withdrawnJul 1, 1948

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • boostrix
  • dpt vaccin
  • dtpa vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06997627Phase 1/Phase 2 (Phase 2)Jun 5, 2025Green Cross Corporation
NCT05613205Phase 1Nov 8, 2022BE Pharmaceuticals, GlaxoSmithKline
NCT05543642Phase 4Oct 5, 2022Oregon Health and Science University
NCT05169905Phase 3Feb 2, 2022GlaxoSmithKline
NCT04138056Phase 2Nov 4, 2019GlaxoSmithKline
NCT04238975Phase 2Oct 14, 2019Green Cross Corporation
NCT03909126Phase 4May 31, 2019Government of France, St. Justine's Hospital
NCT03606096Phase 4Sep 30, 2018Imperial College London, Leiden University, National Institute for Public Health and the Environment, RIVM, Holland, Radboud University, University of London, University of Oxford, University of Turku
NCT03697798Phase 4Apr 18, 2018National Institute for Public Health and the Environment, RIVM, Holland, Spaarne Gasthuis, University of Oxford, University of Turku
NCT03311659Phase 3Jan 26, 2018GlaxoSmithKline
NCT02946190Phase 2Oct 27, 2016BioNet-Asia Co., Ltd., University of Geneva
NCT03035370Phase 1Sep 1, 2016DBV Technologies, University of Geneva
NCT02813486Phase 1/Phase 2 (Phase 2)Jun 1, 2016Green Cross Corporation
NCT02377349Phase 4Oct 14, 2015GlaxoSmithKline
NCT02543918Phase 1Sep 1, 2015Eli Lilly
NCT02555540Phase 4Aug 1, 2015deCODE genetics, European Commission, Ghent University, GlaxoSmithKline, Max Planck Institute, Novartis, Sanofi-Aventis, University of London
NCT02408926Phase 4Apr 1, 2015Chulalongkorn University, Institut Pasteur, Thrasher Research Fund, University of Antwerp
NCT02072525Phase 4Apr 1, 2014GlaxoSmithKline
NCT02052596Phase 3Feb 7, 2014GlaxoSmithKline
NCT01988857Phase 3Feb 1, 2014GlaxoSmithKline
Showing 20 of 37 trials
Page 1 / 2

Organizations

Research & Development (31)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit232242002
Green Cross CorporationFor profit3312016
National Institute for Public Health and the Environment, RIVM, HollandGovernment2012018
University of GenevaAcademic/Hospital2122016
University of LondonAcademic/Hospital2112015
University of OxfordAcademic/Hospital2112018
University of TurkuAcademic/Hospital2012018
BE PharmaceuticalsFor profit1012022
BioNet-Asia Co., Ltd.For profit1012016
Chulalongkorn UniversityAcademic/Hospital1012015
DBV TechnologiesFor profit1112016
deCODE geneticsFor profit1012015
Eli LillyFor profit1112015
European CommissionGovernment1012015
Ghent UniversityAcademic/Hospital1112015
Government of FranceGovernment1012019
Imperial College LondonAcademic/Hospital1012018
Institut PasteurAcademic/Hospital1012015
Leiden UniversityAcademic/Hospital1012018
Max Planck InstituteAcademic/Hospital1012015
31 organizations
Page 1 / 2

Marketing (3)

OrganizationOrg typeRelationshipDate
GlaxoSmithKlineFor profitNDA2May 3, 2005
GlaxoSmithKlineFor profitNDAMay 3, 2005
Sanofi-AventisFor profitNDA2Jun 10, 2005